» Articles » PMID: 21439936

Cardiac Ion Channel Current Modulation by the CFTR Inhibitor GlyH-101

Overview
Publisher Elsevier
Specialty Biochemistry
Date 2011 Mar 29
PMID 21439936
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

The role in the heart of the cardiac isoform of the cystic fibrosis transmembrane conductance regulator (CFTR), which underlies a protein kinase A-dependent Cl(-) current (I(Cl.PKA)) in cardiomyocytes, remains unclear. The identification of a CFTR-selective inhibitor would provide an important tool for the investigation of the contribution of CFTR to cardiac electrophysiology. GlyH-101 is a glycine hydrazide that has recently been shown to block CFTR channels but its effects on cardiomyocytes are unknown. Here the action of GlyH-101 on cardiac I(Cl.PKA) and on other ion currents has been established. Whole-cell patch-clamp recordings were made from rabbit isolated ventricular myocytes. GlyH-101 blocked I(Cl.PKA) in a concentration- and voltage-dependent fashion (IC(50) at +100 mV=0.3 ± 1.5 μM and at -100 mV=5.1 ± 1.3 μM). Woodhull analysis suggested that GlyH-101 blocks the open pore of cardiac CFTR channels at an electrical distance of 0.15 ± 0.03 from the external membrane surface. A concentration of GlyH-101 maximally effective against I(Cl.PKA) (30 μM) was tested on other cardiac ion currents. Inward current at -120 mV, comprised predominantly of the inward-rectifier background K(+) current, I(K1), was reduced by ∼43% (n=5). Under selective recording conditions, the Na(+) current (I(Na)) was markedly inhibited by GlyH-101 over the entire voltage range (with a fractional block at -40 mV of ∼82%; n=8). GlyH-101 also produced a voltage-dependent inhibition of L-type Ca(2+) channel current (I(Ca,L)); fractional block at +10 mV of ∼49% and of ∼28% at -10 mV; n=11, with a ∼-3 mV shift in the voltage-dependence of I(Ca,L) activation. Thus, this study demonstrates for the first time that GlyH-101 blocks cardiac I(Cl.PKA) channels in a similar fashion to that reported for recombinant CFTR. However, inhibition of other cardiac conductances may limit its use as a CFTR-selective blocker in the heart.

Citing Articles

Recommended Tool Compounds for Modifying the Cystic Fibrosis Transmembrane Conductance Regulator Channel Variants.

Han X, Li D, Zhu Y, Schneider-Futschik E ACS Pharmacol Transl Sci. 2024; 7(4):933-950.

PMID: 38633590 PMC: 11019735. DOI: 10.1021/acsptsci.3c00362.


Pharmacological inhibitors of the cystic fibrosis transmembrane conductance regulator exert off-target effects on epithelial cation channels.

Lin J, Gettings S, Talbi K, Schreiber R, Taggart M, Preller M Pflugers Arch. 2022; 475(2):167-179.

PMID: 36205782 PMC: 9849171. DOI: 10.1007/s00424-022-02758-9.


Separating the contributions of SLC26A9 and CFTR to anion secretion in primary human bronchial epithelia.

Larsen M, Choi J, Wang X, Myerburg M, Frizzell R, Bertrand C Am J Physiol Lung Cell Mol Physiol. 2021; 321(6):L1147-L1160.

PMID: 34668421 PMC: 8715023. DOI: 10.1152/ajplung.00563.2020.


Human extrahepatic and intrahepatic cholangiocyte organoids show region-specific differentiation potential and model cystic fibrosis-related bile duct disease.

Verstegen M, Roos F, Burka K, Gehart H, Jager M, de Wolf M Sci Rep. 2020; 10(1):21900.

PMID: 33318612 PMC: 7736890. DOI: 10.1038/s41598-020-79082-8.


The chloride channel cystic fibrosis transmembrane conductance regulator (CFTR) controls cellular quiescence by hyperpolarizing the cell membrane during diapause in the crustacean .

Li A, Sun Z, Liu X, Yang J, Jin F, Zhu L J Biol Chem. 2019; 294(16):6598-6611.

PMID: 30765604 PMC: 6484108. DOI: 10.1074/jbc.RA118.005900.